{'text': 'Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal', 'publisher': {'href': 'https://www.nature.com', 'title': 'Nature.com'}, 'created_at': 'Fri, 02 Oct 2015 07:00:00 GMT', 'description': 'Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 | Blood Cancer Journal  Nature.com', 'url': 'https://news.google.com/rss/articles/CBMiU0FVX3lxTE9QaVdmaXMxUS1GOVVmRTFVckpJNFhmTHpfT21NR2xRV2k1RTBvellmTjdIOTRxUnJjZmV3T3ZhZHlsWXBNTVpaWjBBUlNqZmMwWlBB?oc=5&hl=en-US&gl=US&ceid=US:en'}
